Effect of neonatal reticulocytosis on glucose 6-phosphate dehydrogenase (G6PD) activity and G6PD deficiency

Thanaporn Pimpakan1, Punchalee Mungkalasut2, Pornchinee Tansakul1

  • 1Medical Sciences Program, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.

BMC Pediatrics
|November 24, 2022
PubMed

Insights

Screening newborns for G6PD deficiency is crucial. This study found that high reticulocyte counts do not significantly impact the accurate diagnosis of G6PD deficiency in newborns using automated methods.

Area of Science:

  • Biochemistry
  • Genetics
  • Neonatal Medicine

Background:

  • Glucose-6-phosphate dehydrogenase (G6PD) deficiency screening in newborns is vital for preventing severe health issues like hemolysis and bilirubin encephalopathy.
  • High reticulocyte counts in newborns may potentially interfere with G6PD deficiency diagnosis due to higher enzyme levels in immature red blood cells.

Purpose of the Study:

  • To evaluate the influence of reticulocytosis on G6PD activity measurements in Thai newborns.
  • To validate a novel automated UV-based enzymatic assay for G6PD deficiency detection in neonates.

Main Methods:

  • Measured reticulocyte counts and G6PD activity in 1,015 newborn blood samples.
  • Identified G6PD mutations using TaqMan SNP genotyping, PCR-RFLP, and direct sequencing.
  • Assessed the correlation between reticulocyte levels and G6PD activity, and compared the automated assay's performance against the fluorescent spot test and standard quantitative assay.

Main Results:

  • The automated assay identified G6PD deficiency in 6.5% of newborns, comparable to 5.3% (FST) and 6.1% (standard method).
  • Newborns with G6PD deficiency exhibited significantly higher reticulocyte counts (p < 0.001).
  • The automated method demonstrated high accuracy (99.4%), sensitivity (98.4%), and specificity (99.5%) in detecting G6PD deficiency.

Conclusions:

  • Reticulocytosis does not significantly affect the accurate diagnosis of G6PD deficiency in newborns.
  • The novel automated UV-based enzymatic assay is a reliable tool for G6PD deficiency screening in neonates.
Abstract